{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Quince Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"QNCX"},"Address":{"label":"Address","value":"611 GATEWAY BLVD,SUITE 273, SOUTH SAN FRANCISCO, California, 94080, United States"},"Phone":{"label":"Phone","value":"+1 415 910-5717"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Quince Therapeutics, Inc., is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. The company's Phase 3 lead asset, EryDex, is the first product in development that leverages its proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patient's own red blood cells."},"CompanyUrl":{"label":"Company Url","value":"https://www.quincetx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Brendan Hannah","title":"COO, Chief Financial & Accounting Officer"},{"name":"Dirk Thye","title":"Chief Executive & Medical Officer, Director"},{"name":"Giovanni Mambrini","title":"Chief Technology Officer"},{"name":"Maureen M. Roden","title":"Vice President-Clinical Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}